Eli Lilly Cracks Down on Illicit Retatrutide Sales
Eli Lilly is taking action against the growing black market for its drug retatrutide. The company aims to curb unauthorized distribution and sales.
Related stories
OmicsBank raises $2.25M for cross-border patient data services · Drug development
Ramaswamy-backed pain drug firm to go public via reverse merger · Drug development
CSL Vifor faces revenue slump after Tavneos loses European market access · Drug development
Cytokinetics challenges Bristol Myers Squibb's patent in court · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Eli Lilly targets booming black market for retatrutide.” Browse more stories.